MATN3 (Matrilin 3)

In addition, the protein expression levels of CGB5, MATN3, MARCKS and APOD in GC tissues were significantly higher than those in normal tissues, and correlated with the pathological characteristics of GC patients. The risk model composed of 7 hub genes can accurately evaluate the prognosis of GC patients, which may contribute to the precise and personalized treatment of GC patients.

PDAC cell lines exhibit distinct chemoresistance capabilities. EDC4 and its downstream targets MATN3 and SGCE play significant roles in PDAC multidrug chemoresistance, providing novel insights for treatment.

Silencing the expression of CYP19A1 significantly inhibited the cell proliferation ability and decreased the expression of ER stress-related genes, including ATF4, DDIT3 and XBP1 in STAD. In conclusion, our study developed a novel prognosis prediction signature and identified the novel diagnostic and therapeutic target CYP19A1 for patients with STAD.

This study not only underscores the anticancer potential of α-Pinene but also establishes MATN3 as a critical target and biomarker across a spectrum of cancers. Our findings advocate for further clinical investigations into α-Pinene's therapeutic potential, particularly focusing on its impact on MATN3 and related pathways in diverse cancer contexts.

This study systematically describes a novel DRGPS constructed for predicting HCC prognosis, providing a new approach to risk stratification and treatment options. It also investigates the expression and function of SLC7A11, contributing to further exploration of the molecular mechanism underlying disulfidptosis in HCC, as well as its prognostic and therapeutic implications.

In vitro experiments showed that silencing MATN3 inhibited cell proliferation, migration, and invasion ability. MATN3 is involved in the immune infiltration of cancer and affects the prognosis of many cancer types, and can be used as an immune as well as prognostic biomarker for pan-cancer.

In conclusion, the amino acid metabolism-related prognostic model shows promise as a valuable biomarker for predicting the clinical prognosis, selecting immunotherapy and drug treatment for STAD patients. Furthermore, our study has shed light on the potential value of the MATN3 as a promising strategy for combating the progression of STAD.

In vivo, studies in a mouse model corroborated that co-overexpression of MATN3 and ASPN enhances tumor growth and metastasis. These findings highlight the MATN3-ASPN axis as a potential therapeutic target in GC, offering new insights into the molecular mechanisms driving GC progression.

We provide evidence that the risk-related biological aging measure GrimAge may be a useful predictor of mucositis severity in HNC patients. Salivary monocyte frequency may be protective against mucositis, and this measure could be used as a predictive biomarker while also providing clues into the pathobiology of the disease.

MATN3 is highly expressed in gastric cancer tissues and is associated with various pathological features, drug resistance and poor prognosis. MATN3 holds potential as a diagnostic marker for poor prognosis and may play a role in the malignant behaviors of gastric cancer cells, including proliferation, migration, and invasion.

These findings highlight the importance of M2-like TAMs, provide a new perspective on individualized immunotherapy for GC patients.

Our newly created prognostic signature possesses significant potential as a biomarker for gastric cancer, while MATN3 is identified as an oncogenic factor in gastric cancer. This brings to light new perspectives, which can contribute to enhancing the diagnosis and treatment of gastric cancer.